Breaking News

Karex to bounce back in FY20 — group CEO

www.theedgemarkets.com/article/karex-bou...-%E2%80%94-group-ceo

www.theedgemarkets.com/article/karex-pos...es-social-compliance

What you really should watch to invest well in the stock mark[ /color]

CHONG SER JING
THE GOOD INVESTORS
Jan 02, 2020

The global economy is made up of nearly 7.8 billion people. According to the World Federation of Exchanges, an association for exchanges and clearing houses, there are over 48,000 companies listed in the stock markets around the world.

With so many moving parts, what should we really be watching to invest well in stocks? Two great investors, Ralph Wagner and Warren Buffett, have shown us the way through two fun analogies.

From my personal observations, the US fund manager Ralph Wagner isn't very well-known to the public. But he's one of the real investing greats. From 1970 to 2003, Wagner's Acorn Fund produced an annual return of 16.3 per cent, which was significantly better than the S&P 500 index's gain of 12.1 per cent per year over the same period.

But what makes Wagner unique was his wit. A case in point: His 1997 book about his investing adventures is titled A Zebra in Lion Country. According to a Google Books summary, this is the reason for the book's name:
"Investors are like zebras in lion country: They must settle for meager pickings by sticking in the middle of the herd, or seek richer rewards at the outer edge, where hungry lions lurk."


Coming back to the main topic of this article, here's what Wagner once said:

"There's an excitable dog on a very long leash in New York City, darting randomly in every direction. The dog's owner is walking from Columbus Circle, through Central Park, to the Metropolitan Museum. At any one moment, there is no predicting which way the pooch will lurch.

But in the long run, you know he's heading northeast at an average speed of three miles per hour. What is astonishing is that almost all of the dog watchers, big and small, seem to have their eye on the dog, and not the owner."

If you missed Wagner's analogy, stock markets are the dog while the underlying businesses of stocks are the dog-owner. As investors, we should really be watching businesses (the owner), and not the dog (stock prices).

No matter how the dog is leaping and where it's darting to, it will still end up at the Metropolitan Museum at three miles per hour - because that's the owner's pace, and where he's walking to.

WINNING THE GAME

Warren Buffett is one of the best investors the world has seen. His long-term track records with his investment fund and his conglomerate, Berkshire Hathaway, are astonishing. In his 2013 shareholders' letter, Buffett wrote:

"Games are won by players who focus on the playing field - not by those whose eyes are glued to the scoreboard. If you can enjoy Saturdays and Sundays without looking at stock prices, give it a try on weekdays."

Buffett's message is similar to Wagner's: The playing field (businesses) is the important thing to watch, not the scoreboard (stock prices).

Berkshire's experience is a fantastic example. The chart below shows the percentage change in Berkshire's book value per share and its share price for each year from 1965 to 2018.

There were years when the two percentages match closely, but there were also times when they diverged wildly. A case of the latter is 1974, when Berkshire's book value per share grew by 5.5 per cent even though its share price fell sharply by 48.7 per cent.

But through the 53 years from 1965 to 2018, the book value of Berkshire grew by 18.7 per cent per year while its share price increased by 20.5 per cent annually. An 18.7 per cent input over the long run has resulted in a closely-matched output of 20.5 per cent.

FOCUSING ON BUSINESSES

READ ALSO
Why I invest only in stocks
Why I invest only in stocks
It's not a coincidence that Wagner and Buffett are saying the same thing. To really do well in the stock market, we should be watching businesses, not stock prices. After all, investment performance converges with business performance over the long run.

I want to end off with a quote from Peter Lynch, himself another legend in the investing business. During his entire tenure as the manager of the Fidelity Magellan Fund from 1977 to 1990, Lynch produced an annual return of 29 per cent. In a 1994 lecture (link leads to a video; see the 14:20 min mark), he said:

"I'm trying to convince people there is a method. There are reasons for stocks to go up. This is very magic: it's a very magic number, easy to remember. Coca-cola is earning 30 times per share what they did 32 years ago; the stock has gone up 30 fold. Bethlehem Steel is earning less than they did 30 years ago - the stock is half its price 30 years ago.

Stocks are not lottery tickets. There's a company behind every stock - if the company does well, the stock does well. It's not that complicated."

This article was first published in The Good Investors. All content is displayed for general information purposes only and does not constitute professional financial advice.

www.asiaone.com/money/what-you-really-sh...st-well-stock-market

Impact BioMedical, Inc’s Equivir performs well against a board range of viruses in testing by its Scientific Research Partner and preparations are underway for
testing of Equivir against COVID-19


SINGAPORE, 2 March 2020 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”) wishes to announce today that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. (“GRDG”), recently conducted an additional round of testing of Equivir, a patented medical treatment and preventative drug, against a broad range of viruses. The tests results revealed that Equivir performed well against a broad range of viruses and validates the results of previous laboratory testing conducted at multiple independent facilities. These tests demonstrate the ability of Equivir to control viruses responsible for deadly infectious diseases. The unique ability of Equivir to inhibit
viruses makes it a promising candidate for the treatment of COVID-19, the disease
caused by SARS-CoV-2 or severe acute respiratory syndrome coronavirus 2.
According to the U.S. Centers for Disease Control and Prevention or CDC, COVID-19 causes respiratory illnesses in people and can spread from person to person. SARS-CoV-2 was first identified in Wuhan, The People’s Republic of China (“China”). As at 20 February 2020, the World Health Organisation reported 75,748 confirmed cases of COVID-19 of which China had 74,675 confirmed cases, although many estimate the numbers to be much higher. GRDG had previously contracted multiple independent scientific research laboratories to
test Equivir against a broad range of viruses including Influenza, Rhinovirus (one of the causes of the common cold) and Ebola. GRDG has recently conducted an additional round of testing of Equivir utilising the non-clinical and pre-clinical services program offered by the U.S. National Institute of Allergy and Infectious Diseases which is part of the U.S. National Institutes of Health. In this recent testing, Equivir demonstrated in vitro efficacy against multiple strains of Influenza (H1N1, H3N2, H5N1, H7N9, Influenza B and Parainfluenza 3), Human Rhinovirus-14, Human Coronavirus-A and Ebola. This recent testing validates the results of previous laboratory testing.Press Release – Impact BioMedical, Inc’s antivial drug, Equivir, performs well against a board range of viruses in independent testing and preparations are underway for independent testing of Equivir against COVID-19
2 March 2020
The research is headed by Mr. Daryl Thompson, GRDG’s Director of Scientific Initiatives, who is an entrepreneur and biochemist known for multiple healthcare technology innovations. “Equivir was designed as a solution for guidelines established by Project Bioshield,” says Mr. Thompson. “We are moving forward to establish Equivir as a potential therapeutic to mitigate COVID-19.”
Mr. Chan Heng Fai, Executive Chairman, Executive Director and Chief Executive Officer of SeD, said, “I am gratified to have this further validation on the technologies we have and we are excited to be able to contribute to the current situation in the best possible way we can.”.
GRDG’s Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr. who was the former United States Assistant Surgeon General and the former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention or CDC. He said that “The ability of Equivir to be validated and quickly deployed is a solution to an issue that is of great interest to the global public health community.”.
GRDG is also advised by Lieutenant Colonel William H. Lyerly Jr., a retired U.S. Army Medical Service Corps Officer and a retired Career Senior Executive / Scientific Professional from the U.S. Department of Homeland Security. Lieutenant Colonel Lyerly also served as a senior official in the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly states that “this latest outbreak illustrates the speed at which pandemics can explode and the need for easily administered, effective, and versatile treatments. Equivir's potential to help treat and prevent illnesses caused by this and other future outbreaks is crucial for stopping the spread of the Coronavirus”

Shareholders and potential investors of SeD Company should note that there is no certainty or assurance as at the date of this Press Release that Equivir will be licensed or close to monetisation. Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional
advisers if they have any doubt about the actions they should take.

www.straitstimes.com/business/economy/ma...onday-what-to-expect

MAS set for aggressive action come Monday: What to expect

SINGAPORE (BLOOMBERG) - Singapore' s central bankers are poised to take unprecedented action on Monday (March 30) to bolster financial markets and support an economy facing a severe recession.

lol

[b]iCann[/b] wrote: Impact BioMedical, Inc’s Equivir performs well against a board range of viruses in testing by its Scientific Research Partner and preparations are underway for
testing of Equivir against COVID-19


SINGAPORE, 2 March 2020 – Singapore Exchange-listed Singapore eDevelopment Limited (Stock Code 40V) (“SeD”) wishes to announce today that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. (“GRDG”), recently conducted an additional round of testing of Equivir, a patented medical treatment and preventative drug, against a broad range of viruses. The tests results revealed that Equivir performed well against a broad range of viruses and validates the results of previous laboratory testing conducted at multiple independent facilities. These tests demonstrate the ability of Equivir to control viruses responsible for deadly infectious diseases. ..............
.

SINGAPORE E-DEVELOPMENT jumped 30% today!